Loading
RON is a receptor kinase from the same family as MET; multi-kinase drugs such as crizotinib and cabozantinib hit it as well as their main targets.
Macrophage-stimulating protein receptor (RON, gene MST1R) is the sister receptor of MET, activated by MSP and overexpressed or aberrantly spliced in several carcinomas, where it promotes invasion and macrophage-driven inflammation. It is not a primary approval target, but crizotinib, cabozantinib and other MET-family inhibitors inhibit it and ChEMBL lists it among their targets.
In plain words · RON is a receptor kinase from the same family as MET; multi-kinase drugs such as crizotinib and cabozantinib hit it as well as their main targets.
RON is a receptor kinase from the same family as MET; multi-kinase drugs such as crizotinib and cabozantinib hit it as well as their main targets.
A receptor tyrosine kinase signalling through PI3K, MAPK and beta-catenin pathways; short isoforms act as constitutively active oncogenes.
No product in this corpus aims at RON receptor (MST1R) yet. Kinases are switched on by binding ATP inside the cell, so most drugs are small molecules shaped to plug that ATP pocket.
Tumour-associated overexpression: HPA finds the RNA tissue enhanced in normal intestine, skin 1, stomach 1, so the tumour and the normal tissue it comes from share the target and the medicine relies on the difference in level. HPA MST1R: RNA tissue enhanced (intestine 18 nTPM, skin 1 30 nTPM, stomach 1 26 nTPM); high antibody staining in 5 normal tissues; highest cancer staining melanoma (10 of 12 high). Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Lung cancer (all types), Colorectal cancer); Open Targets associates it with 1 specific cancer type at or above 0.5 (non-small cell lung carcinoma). (Rule 7 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas MST1R tissue; Human Protein Atlas MST1R pathology; Open Targets ENSG00000164078 associations
First described 1993. Earliest sequence paper UniProt cites for the protein: Ronsin et al, Oncogene, 1993, "A novel putative receptor protein tyrosine kinase of the met family". Source.
A receptor tyrosine kinase signalling through PI3K, MAPK and beta-catenin pathways; short isoforms act as constitutively active oncogenes.
RNA: tissue enhanced (intestine 18 nTPM, skin 1 30 nTPM, stomach 1 26 nTPM), detected in many normal tissues.
Medium: Adipose tissue, Adrenal gland, Appendix, Breast, Bronchus, Caudate, Cerebellum, Cerebral cortex.
Medium only: breast cancer, carcinoid, cervical cancer, colorectal cancer.
HPA MST1R tissue · HPA MST1R pathology · HPA protein class: CD markers, FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Metastatic cancer | all% | Signalling protein present in most cells (RON receptor kinase, a secondary target of MET drugs); drugs act on the pathway rather than on a mutation that selects patients, so no prevalence applies. |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
Query for this target: (TITLE:"RON receptor" OR ABSTRACT:"RON receptor" OR TITLE:"MST1R" OR ABSTRACT:"MST1R") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about RON receptor (MST1R), not a curated reading list.
Shares MET, Non-small-cell lung cancer.
Shares Cabozantinib, Non-small-cell lung cancer.
Shares Crizotinib, Non-small-cell lung cancer.
Shares Crizotinib, Cabozantinib.
Shares Crizotinib, Non-small-cell lung cancer.
Shares Crizotinib, Non-small-cell lung cancer.
Shares MET, Colorectal cancer.
Shares Crizotinib, MET, Non-small-cell lung cancer.